



Phase 3 Study of NPC now Enrolling in UK

[TransportNPC™](#) (Intravenous 2-hydroxypropyl- β -cyclodextrin), is a clinical trial evaluating the safety and efficacy of a potential disease modifying therapy to treat NPC. This study is available for both pediatric and adult patients. Two centers in the UK are now enrolling patients, and a third one is expected to begin enrollment soon. If you are interested, please discuss with your treating physician, or reach out to one of the centers listed below for more information.

Julian AJ Raiman MBBS MSc MRCP(Lond)
Birmingham Children's Hospital
Steelhouse Lane
Birmingham
B4 6NH
IMD Secretaries: 0121 333 9907/9908
IMD Fax: 0121 333 9909

Reena Sharma
Honorary Senior Lecturer, The Mark Holland Metabolic Unit,
Salford Royal Foundation NHS Trust
Ladywell NW2- 2nd Floor,
Salford, UK. M6 8HD
Tel: 0044-161-2064365

Dr Robin Lachmann FRCP PhD
Consultant in Inherited Metabolic Disease
National Specialty Advisor, Metabolic Disorders
University College London Hospitals
National Hospital for Neurology and Neurosurgery
Queen Square
London WC1N 3BG